Technovax, Inc.

Mannkind Corporation

Jose M Galarza

George R Martin

Demetrius Matassov

Helene Boigard

Andrea Leone-Bay

Chad C Smutney

Marshall L Grant

Velasco Cimica

Hector Munoz

Hélène Boigard

Described herein are influenza virus-like particles (VLPs) that display on truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these VLPs.

Universal virus-like particle (VLP) influenza vaccines

Flavivirus virus-like particles (VLPs) are provided that display on their surfaces antigenic flavivirus proteins. The VLPs include at least one flavivirus structural protein and at least one non-structural flavivirus protein. A DNA construct that includes sequences encoding flavivirus viral proteins used to assemble the flavivirus VLP is also provided. A method of producing flavivirus VLPs by introducing one or more the DNA constructs into a host cell is also provided. An immunogenic composition that includes the flavivirus VLP is also provided.

Flavivirus and alpha virus virus-like particles (VLPS)

Described herein are virus-like particles (VLPs) that display on their surfaces antigenic paramyxovirus (e.g., RSV and/or MPV) proteins. Also described are methods of making and using these VLPs.

Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine

Described herein are flavivirus virus-like particles (VLPs) that display on their surfaces antigenic flavivirus proteins. Also described are methods of making and using these VLPs.

Flavivirus and alphavirus virus-like particles (VLPS)

Dry powder inhalable compositions and methods for using and making the compositions are disclosed for vaccinating a subject against disease. In particular, the compositions are inhalable dry powders useful for preventing and/or treating diseases caused by microorganisms, for example, microorganisms such as viral or bacterial pathogens, including, the influenza virus. In particular, the method comprises the administration of an inhalable composition comprising virus-like particles and/or specific protein/s or antigenic peptides, peptide fragments and/or derivatives thereof using a dry powder drug delivery system.

Inhalable vaccine compositions and methods

Influenza virus-like particles (VLPs) comprising influenza antigenic polypeptides are described. Also described are compositions comprising these VLPs as well as methods of making and using these VLPs.

Influenza virus-like particle (VLP) compositions

Polyvalent influenza virus-like particles (VLPs) comprising influenza antigenic polypeptides are described. Also described are compositions comprising these polyvalent VLPs as well as methods of making and using these VLPs.

Growing community of inventors

Elmsford, NY, United States of America

Jose M Galarza